CV Sciences, Inc. (OTCPK:CVSI) is looking for M&A. During the CV Sciences 2025 Fiscal Year-End and Fourth Quarter Earnings Call, Joseph Dowling, Chief Executive Officer, said, "Our strategy is centered on 3 primary areas: Product innovation; cost efficiency; and strategic M&A. Our third focus area is M&A, which remains an important part of our growth strategy. Over the past 2 years, we completed the acquisitions of Cultured Foods and Elevated Softgels, both of which are contributing to scale, efficiency and diversification. We continue to evaluate additional opportunities that offer strong strategic and financial alignment, and we remain actively engaged with our advisers".
"We expect consolidation across the hemp and cannabis industries to continue, and we intend to remain an active participant where it creates strategic value".
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox brands in the healthcare market sector, including nutraceutical, beauty care, specialty foods, and pet products. Its hemp extracts, and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). Its +PlusCBD line of products are available in softgels, tinctures, topicals, and gummies. Its Cultured Foods and Lunar Fox cater to individuals seeking vegan, gluten-free, or flexitarian options for a nutritious and satisfying culinary experience. Its +PlusHLTH is a line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance and increased vitality.
